Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences (Nasdaq: RKDA) reported second quarter 2026 revenues of $1.44 million, down 1% year over year, and first half revenues of $2.54 million, down 4%.

Rhea-AI Summary

Arcadia Biosciences (Nasdaq: RKDA) reported second quarter 2026 revenues of $1.44 million, down 1% year over year, and first half revenues of $2.54 million, down 4%. Q2 loss from continuing operations was $0.5 million, while net loss attributable to common stockholders widened to $6.3 million, or $2.09 per share.

First half 2026 net loss attributable to common stockholders was $10.7 million, or $4.19 per share. According to the company, Q2 net results reflected a $2.8 million unrealized loss on Above Food stock, a $5.4 million valuation loss on a June 2026 PIPE, and offering costs. Net cash used in operating activities was $319,000 in Q2, and Arcadia ended the quarter with $4.2 million in cash after a $4 million June private placement. SG&A expenses declined by $1.0 million in Q2 and $1.6 million in the first half versus 2025, driven by lower employee costs and no M&A fees. Zola revenues fell 4% in the first half, but July Zola sales exceeded $740,000 and surpassed $1 million through the first week of August, following resolution of inventory and shipping issues.

Positive

• Net cash used in operations only $319K in Q2 2026
• Cash balance $4.2M at Q2 2026 quarter-end after financing
• SG&A expense reduction $1.0M in Q2 and $1.6M in first half 2026
• Private placement proceeds $4.0M gross raised in June 2026
• Strong July Zola sales over $740K, exceeding $1M through first week of August

Negative

• Revenues declined 1% in Q2 and 4% in first half 2026
• Net loss to common $6.3M in Q2 2026 versus $4.5M in 2025
• First half net loss to common $10.7M versus $1.9M in 2025
• Operating expenses first half up $1.2M, a 45% increase year over year
• Unrealized loss on Above Food stock $2.8M in Q2, $4.3M in first half 2026
• PIPE and inducement financing losses $5.4M PIPE valuation loss plus $2.9M inducement offer loss in first half 2026

News Explained

The company plans to launch a new 1-liter espresso product in Q4 2026, with pre-launch commitments from its two largest customers, followed by three additional planned products in the first half of 2027; these are future plans, not completed launches.

Argus Aug 14 session 8 alerts

+5.28% close to close 10.7x rel. volume Open Argus

Details

Market move: RKDA +5.28% in the Aug 14 session. 2Q26 earnings report

+9.1% Peak in 43 min

$1.74M Market Cap

On Aug 14, the first trading day after this news, RKDA closed 5.28% above the previous close. Argus tracked a peak move of +9.1% during that session. Our momentum scanner recorded 8 alerts for this stock that day. Relative volume reached 10.7x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 14 session.

Key Figures

Operating cash used: $319K Private placement: $4 million Cash balance: $4.2 million +5 more

Operating cash used

$319K

Second quarter 2026

Private placement

$4 million

Gross proceeds raised in June 2026

Cash balance

$4.2 million

At end of second quarter 2026

July sales

$740K

Monthly Zola sales

August sales

$1 million

Zola sales through first week of August

Total revenues

$1.443 million

Second quarter 2026, versus $1.455 million in 2025

Net loss

$6.3 million

Second quarter 2026

Net loss per share

$2.09 per share

Second quarter 2026

Previous Earnings Reports

5 past events · Latest: May 14

Same Type 5 events

1. May 14

   First-quarter earnings

   24h Move

   -10.7%

   Revenue declined while net loss and financing-related charges increased.

2. Mar 26

   Fourth-quarter earnings

   24h Move

   -3.3%

   Revenue declined despite lower expenses and improved quarterly net loss.

3. Nov 07

   Third-quarter earnings

   24h Move

   -2.2%

   Credit loss and lower cash offset distribution-driven revenue growth.

4. Aug 14

   Second-quarter earnings

   24h Move

   +5.6%

   Revenue and Zola sales increased, despite a credit loss.

5. May 08

   First-quarter earnings

   24h Move

   -0.2%

   Revenue, Zola sales, and net income improved with lower operating expenses.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, sg&a, pipe financing, contingent liability

4 terms

private placement financial

"Arcadia closes $4 million private placement; ends second quarter"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

sg&a financial

"our SG&A expenses declined by $1,000,000 versus the same period"

SG&A stands for Selling, General, and Administrative expenses. It includes the costs a company spends on selling products, running the business day-to-day, and managing staff, like advertising, rent, and salaries. These expenses matter because they affect how much profit a company can make from its sales.

pipe financing financial

"a $5.4 million valuation loss relating to the company’s June 2026 PIPE financing"

Pipe financing is a way for companies to raise money quickly by selling new shares or bonds directly to investors, often before their stock is publicly traded or in the early stages of a project. It’s similar to a company securing a loan from investors, providing quick capital needed for growth or operations. For investors, it can offer opportunities for early involvement and potentially higher returns, but it may also carry increased risk due to the immediate nature of the deal.

contingent liability financial

"a $1 million gain from the elimination of a contingent liability"

A contingent liability is a potential financial obligation that may or may not happen, depending on the outcome of a future event. It’s like a promise to pay if certain circumstances occur, such as if a court rules against a company or a loan guarantee is called upon. For investors, understanding these liabilities helps gauge possible risks that could affect a company's financial health.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Net cash used in operating activities only $319K in the second quarter –
– Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash –
– July monthly Zola^® sales top $740K; exceed $1 million through first week of August –

DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2026.

“We were very pleased with our second quarter financial results,” said T.J. Schaefer, CEO of Arcadia. “Our cash used in operating activities was only $319,000 during the quarter, we have a cash balance of $4.2 million at the end of the quarter and our SG&A expenses declined by $1,000,000 versus the same period of last year, to an all-time low.”

Schaefer continued, “We believe Zola^® has reached an inflection point and is now entering a new growth phase. While second quarter sales were flat compared to last year due to low inventory and shipping delays, these issues have been corrected resulting in July sales that were more than half of the sales for the entire second quarter that we are reporting today.

“In addition, after raising $4 million in gross proceeds through a private placement in June, we now have the cash to fund Zola’s growth, which we expect to accelerate as a result of new products we are bringing to market. In Q4 2026, we will launch a 1-liter espresso with a new formula that tastes more like coffee than coconut water and has pre-launch commitments from our two largest customers. In the first half of 2027, we have a plan to launch three new additional products that we are very excited about,” Schaefer added.

($ in thousands) Arcadia Biosciences, Inc. Financial Snapshot (Unaudited)
	Three Months Ended June 30,								Six Months Ended June 30,
	2026		2025	Favorable/ (Unfavorable)					2026		2025		Favorable/ (Unfavorable)
				$		%							$		%
Total revenues	1,443		1,455	(12)		(1%)			2,543		2,655		(112	)	(4%)
Total operating expenses	1,939		1,956	17		1%			3,818		2,626		(1,192	)	(45%)
(Loss) income from continuing operations	(496	)	(501)	5		1%			(1,275	)	29		(1,304	)	(4497%)
Net loss attributable to common stockholders	(6,266	)	(4,458)	(1,808)		(41%)			(10,651	)	(1,859	)	(8,792	)	(473%)

More detailed financial information is included in the company’s Report on Form 8-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), available in the Investors section of the company’s website under SEC Filings.

Revenues
Revenues decreased slightly during the second quarter of 2026 compared to the same period in 2025. Zola revenues decreased $112,000, or 4%, during the first half of 2026 compared to the same period in 2025. The shortfalls in both the second quarter and first half of 2026 were primarily driven by low inventory balances and longer-than-expected shipping times.

Operating Expenses
Total operating expenses decreased slightly during the second quarter of 2026 despite a $1.0 million decrease in SG&A as 2025 operating expenses included a $1 million gain from the elimination of a contingent liability. Total operating expenses increased by $1.2 million during the first half of 2026 despite a $1.6 million decrease in SG&A due to $2.8 million in gains recognized in the first half of 2025.

Cost of revenues were essentially unchanged during the second quarter and first half of 2026 compared to the same periods in 2025.

SG&A decreased by $1.0 million and $1.6 million during the second quarter and first half of 2026, respectively, compared to the same periods in 2025, driven by lower employee costs and the absence of M&A fees in 2026.

Other operating expenses decreased by $1.0 million during the second quarter of 2026 compared to the same period in 2025 due to a $1.0 million gain from the elimination of a contingent liability in the second quarter of 2025. Other operating expenses decreased by $2.8 million during the first half of 2026 compared to the same period in 2025 due to a $2.0 million gain from the elimination of a contingent liability as well as a $750,000 gain related to the sale of intangible assets that occurred in the first half of 2025.

Net Loss Attributable to Common Stockholders
Net loss attributable to common stockholders for the second quarter of 2026 was $6.3 million, or $2.09 per share, compared to a net loss of $4.5 million, or $3.26 per share, for the second quarter of 2025. The second quarter of 2026 included a $2.8 million unrealized loss related to the Above Food stock held by the company, a $5.4 million valuation loss relating to the company’s June 2026 PIPE financing transaction, and offering costs of $651,000, which were offset by a gain related to the change in fair value of common stock warrant and option liabilities. The second quarter of 2025 included a $4.5 million credit loss related to the note receivable from Above Food, which was offset by a $1.1 million unrealized gain related to the Above Food stock.

Net loss attributable to common stockholders for the first half of 2026 was $10.7 million, or $4.19 per share, compared to a net loss of $1.9 million, or $1.36 per share, for the first half of 2025. The first half of 2026 included a $4.3 million unrealized loss related to the Above Food stock, a $2.9 million loss on the company’s January 2026 inducement offer financing transaction, a $5.4 million valuation loss on the June 2026 PIPE, and offering costs of $1.1 million, which were offset by a $4.3 million gain related to the change in fair value of common stock warrant and option liabilities. The first half of 2025 included a $4.5 million credit loss related to the note receivable from Above Food, which was offset by a $1.1 million unrealized gain related to the Above Food stock and $1.3 million gain related to the change in fair value of common stock warrant and option liabilities.

About Arcadia Biosciences, Inc.
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations concerning the company and its products, including, but not limited to, statements relating to Zola products and sales, the company’s growth, cash position, operating costs, financial performance, evaluation of possible strategic alternatives and transactions, and the impact on shareholder value. Undue reliance should not be placed on any forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from the results anticipated by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia’s Annual Report on Form 10-K for the year ended December 31, 2025 (the 2025 Form 10-K), and other filings that the company makes with the SEC. Forward-looking statements concerning anticipated future activities also assume that the company has sufficient funding to continue its operations and planned activities, which may not be the case. As described in greater detail in the 2025 Form 10-K and in the company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026, the company will require additional funding to continue its operations and planned activities. There are no assurances that required funding will be available at all or will be available in sufficient amounts or on reasonable terms. The company may seek to raise additional funds through equity or debt financings, through transactions involving its other assets, or through other transactions, and may seek other strategic alternatives and transactions. Any sale of additional equity securities could result in dilution to company stockholders. Reported results should not be considered as an indication of future performance. Forward-looking statements made in this press release speak only as of the date hereof, and except as required by law, Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements or to reflect events or circumstances arising after the date of this press release.

Arcadia Biosciences Contact:
T.J. Schaefer
ir@arcadiabio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Arcadia Biosciences (RKDA) perform financially in Q2 2026?

Arcadia Biosciences reported Q2 2026 revenues of $1.44 million, down 1% year over year, and a net loss attributable to common stockholders of $6.3 million. According to Arcadia, loss from continuing operations was $0.5 million, with results affected by several non-cash valuation items.

What were Arcadia Biosciences (RKDA) first half 2026 results as of June 30, 2026?

For the first half of 2026, Arcadia Biosciences generated $2.54 million in revenues, a 4% decline versus 2025, and a net loss attributable to common stockholders of $10.7 million, or $4.19 per share. According to Arcadia, first half loss from continuing operations was $1.28 million.

How is Arcadia Biosciences (RKDA) managing cash and operating expenses in Q2 2026?

Arcadia Biosciences used only $319,000 in net cash for operating activities in Q2 2026 and ended the quarter with $4.2 million in cash. According to Arcadia, SG&A expenses fell by $1.0 million in Q2 and $1.6 million in the first half compared to 2025.

What impacted Arcadia Biosciences (RKDA) net loss in Q2 and first half 2026?

Net loss was heavily influenced by non-operating items, including a $2.8 million unrealized loss on Above Food stock and a $5.4 million valuation loss on the June 2026 PIPE. According to Arcadia, first half results also included a $2.9 million inducement offer loss.

How did Zola sales and revenues trend for Arcadia Biosciences (RKDA) in 2026?

Zola revenues declined $112,000, or 4%, in the first half of 2026 compared to 2025, mainly due to low inventory and shipping delays. According to Arcadia, July 2026 Zola sales exceeded $740,000 and surpassed $1 million through the first week of August after these issues were resolved.

What new products and growth plans did Arcadia Biosciences (RKDA) outline for Zola?

Arcadia plans to launch a 1-liter Zola espresso with a new formula in Q4 2026, with pre-launch commitments from its two largest customers. According to Arcadia, three additional Zola products are planned for launch in the first half of 2027.

What financing activity did Arcadia Biosciences (RKDA) complete in June 2026?

In June 2026, Arcadia Biosciences closed a private placement raising $4 million in gross proceeds, which contributed to a $4.2 million cash balance at quarter-end. According to Arcadia, Q2 results also reflected a $5.4 million valuation loss related to this PIPE financing transaction.